Clinical Trial

Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1, monocentric, open labeled, no profit "Microdose" trial. A single microdose of the new \[68Ga\]Ga-R54 PET radiopharmaceutical directed against CXCR4 will be injected into patients with advanced solid tumor or multiple myeloma to evaluate the binding.
Trial Details
NCT Number NCT07577206
Lead Sponsor National Cancer Institute, Naples
Conditions Advanced Solid Tumor, Multiple Myeloma
Enrollment 10 participants
Start Date 2025-01-24
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-11